Inovio Pharmaceuticals
INO
114 hedge funds and large institutions have $142M invested in Inovio Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 41 increasing their positions, 31 reducing their positions, and 9 closing their positions.
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
72% more call options, than puts
Call options by funds: $5.94M | Put options by funds: $3.46M
32% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 31
9% more funds holding
Funds holding: 105 → 114 (+9)
0.14% more ownership
Funds ownership: 3.26% → 3.4% (+0.14%)
26% less capital invested
Capital invested by funds: $193M → $142M (-$50.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$3.14M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.98M |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$2.07M |
| 4 |
Capstone Investment Advisors
New York
|
+$1.82M |
| 5 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.66M |
| 2 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$3.59M |
| 3 |
IG
ING Group
Amsterdam,
Netherlands
|
-$2.2M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.22M |
| 5 |
GC
Globeflex Capital
San Diego,
California
|
-$996K |
INO Hedge Fund Activity: Q3 2015 in Review
114 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2015, worth a combined $142M — down 26% from $193M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new INO positions and 9 closed out — a net gain of 9 holders — while 41 added to existing stakes and 31 trimmed.
The largest buyer was State Street, adding an estimated $3.14M. The largest seller was Susquehanna International Group, cutting an estimated $5.66M.
- 114 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2015, up from 105 in Q2 2015.
- Funds reported $142M of Inovio Pharmaceuticals stock for Q3 2015, down 26% quarter-over-quarter.
- 18 funds opened new Inovio Pharmaceuticals positions in Q3 2015 and 9 closed out, a net change of +9 holders.
- The largest Inovio Pharmaceuticals buyer in Q3 2015 was State Street, an estimated $3.14M added.
- The largest Inovio Pharmaceuticals seller in Q3 2015 was Susquehanna International Group, an estimated $5.66M sold.
Based on aggregated 13F filings for Q3 2015.